Journals / Turkish Journal of Pharmaceutical Sciences / 2022 / Cilt: 19 - Sayı: 1

Ameliorative Potential of Rosuvastatin on Doxorubicin-induced Cardiotoxicity by Modulating Oxidative Damage in Rats

Sıçanlarda Oksidatif Hasar Modülasyonuyla Doksorubisinin İndüklediği Kardiyotoksisite Üzerine Rosuvastatinin İyileştirici Potansiyeli

Pages
28–34
Publication Date
2022-11-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Acute administration of DOXO resulted in a marked rise of cardiac marker enzymes that confirms the myocardial damage compared to control animals whereas administration of ROSS (10 mg/kg, p.o.) resulted in the significant reduction of CK-MB, LDH levels (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The study aimed to explore the in vivo protective potential of rosuvastatin (ROSS), an oral antihyperlipidemic drug against doxorubicin (DOXO) induced cardio toxicity in rats.
📊
Key Findings & Data:Materials and Methods: Cardiac toxicity was induced by DOXO injection (10 mg/kg, i.p.), once on the 20th day of the experiment.
💡
Conclusion & Impact:Results: Acute administration of DOXO resulted in a marked rise of cardiac marker enzymes that confirms the myocardial damage compared to control animals whereas administration of ROSS (10 mg/kg, p.o.) resulted in the significant reduction of CK-MB, LDH levels (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: The study aimed to explore the in vivo protective potential of rosuvastatin (ROSS), an oral antihyperlipidemic drug against doxorubicin (DOXO) induced cardio toxicity in rats. Materials and Methods: Cardiac toxicity was induced by DOXO injection (10 mg/kg, i.p.), once on the 20th day of the experiment. Except for the control rats, all were received DOXO and the study was continued for up to 21 days. The influence of ROSS on acute treatment was analyzed by quantification of cardiac marker enzymes such as creatine kinase-MB (CK-MB), lactate dehydrogenase (LDH) and liver marker enzymes like aspartate aminotransferase (AST), alanine aminotransferase (ALT) along with the measurement of in vivo antioxidants like superoxide dismutase and catalase. To observe histological changes of myocardial tissue hematoxylin and eosin staining were used. Results: Acute administration of DOXO resulted in a marked rise of cardiac marker enzymes that confirms the myocardial damage compared to control animals whereas administration of ROSS (10 mg/kg, p.o.) resulted in the significant reduction of CK-MB, LDH levels (p

Özet

Amaç: Çalışma, sıçanlarda doksorubisin (DOXO) indüklediği kardiyotoksisiteye karşı oral antihiperlipidemik bir ilaç olan rosuvastatinin (ROSS) in vivo koruyucu potansiyelini araştırmayı amaçlamıştır. Kardiyak toksisite, deneyin 20. gününde bir kez DOXO enjeksiyonu (10 mg/kg, i.p.) ile indüklenmiştir. Kontrol sıçanları hariç tümüne DOXO verildi ve çalışmaya 21 güne kadar devam edilmiştir. Akut uygulamada ROSS’nin etkisi, süperoksit dismutaz ve katalaz gibi in vivo antioksidanların ölçümü ile birlikte kreatin kinaz-MB (CK-MB), laktat dehidrojenaz (LDH) gibi kardiyakgösterge enzimlerin ve aspartat aminotransferaz (AST), alanin aminotransferaz (ALT) gibi karaciğer gösterge enzimlerinin kantitatif tayini ile analiz edilmiştir. Miyokardiyal dokudaki histolojik değişiklikleri gözlemlemek için hematoksilen ve eozin boyaması kullanılmıştır. DOXO’nun akut uygulaması, kontrol hayvanlarına kıyasla miyokardiyal hasarı doğrulayan kardiyak gösterge enzimlerinde belirgin bir artışa neden olurken, ROSS (10 mg/kg, p.o.) uygulaması CK-MB, LDH düzeylerinde (p

🔖

Cite This Article

RAJANGAM, J., KRISHNAN, N., PALEI, N. N., BHATT, S., MATHUSOOTHANAN, K., DAS, M. K., DAS, S. (2022). Ameliorative Potential of Rosuvastatin on Doxorubicin-induced Cardiotoxicity by Modulating Oxidative Damage in Rats. Turkish Journal of Pharmaceutical Sciences, Cilt: 19 - Sayı: 1, 28–34. https://ajindex.com/articles/613594

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombolà L, Carnuccio R, Iuvone T, D’Acquisto F, Di Rosa M. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther. 2000;292:156-163
  2. Singal PK, Pierce GN. Adriamycin stimulates low-affinity Ca2+ binding and lipid peroxidation but depresses myocardial function. Am J Physiol Heart Circ Physiol. 1986;250:H419-H425
  3. Thillaivanan S, Parthiban P, Kanakavalli K, Sathiyarajeshwaran P. A review on “Kapa Sura Kudineer”-a Siddha formulary prediction for swine flu. Int J Pharm Sci Drug Res. 2015;7:376-383
  4. Arya V, Gupta VK. Chemistry and pharmacology of plant cardio protective: a review. Int J Pharm Sci. 2011;2:1156-1167
  5. Nazish J, Ur-Rahman, Shoukat A. Cardioprotective, and antilipidemic potential of Cyprus rotundas in chemically induced cardiotoxicity. Int J Agric Biol. 2012;14:989-992
  6. Geisberg CA, Sawyer DB. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr Hypertens Rep. 2010;12:404-410
  7. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52:1213-1225
  8. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185-229
  9. Konorev EA, Kotamraju S, Zhao H, Kalivendi S, Joseph J, Kalyanaraman B. Paradoxical effects of metalloporphyrins on doxorubicin-induced apoptosis: scavenging of reactive oxygen species versus induction of heme oxygenase-1. Free Radic Biol Med. 2002;33:988
  10. Monetti M, Canavesi M, Camera M, Parente R, Paoletti R, Tremoli E, Corsini A, Bellosta S. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. Pharmacol Res. 2007;55:441-449
  11. Funderburg NT, Jiang Y, Debanne SM, Labbato D, Juchnowski S, Ferrari B, Clagett B, Robinson J, Lederman MM, McComsey GA. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;68:396-404
  12. Miida T, Takahashi A, Ikeuchi T. Prevention of stroke and dementia by statin therapy: experimental and clinical evidence of their pleiotropic effects. Pharmacol Ther. 2007;113:378-393
  13. Duarte T, da Cruz IB, Barbisan F, Capelleto D, Moresco RN, Duarte MM. The effects of rosuvastatin on l